Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pharmacyclics has reported encouraging results from its preclinical program evaluating PCI-32765, an orally available, selective inhibitor of Bruton's tyrosine kinase, or Btk, in B-cell receptor modulated diseases such as lymphomas and autoimmune diseases.
Subscribe to our email newsletter
Researchers conducted studies with PCI-32765 examining the downstream signaling events in the B-cell receptor (BCR) signal transduction pathways. In vitro drug treatment of B-cell lymphomas blocked BCR mediated signaling and in vivo drug treatment of lymphoma-bearing animal models resulted in inhibition of tumor growth.
Normal human B-cell activation was also inhibited by drug treatment in vitro. PCI-32765 also showed significant activity in animal models of arthritis.
Joseph Buggy, vice president of research at Pharmacyclics, said: “These studies highlight the importance of Btk in immune mediated diseases. Further, these data support our ongoing IND-enabling studies for PCI-32765, and our plans for an anticipated clinical trial later this year.”